Head & Neck Cancers

Joseph A. Califano, MD, discusses how surgery factors into modern multidisciplinary care for patients with head and neck cancer.

Michael Bouvet, MD, highlights the evolving surgical options in the thyroid cancer field

Assuntina G. Sacco, MD, discusses the importance of multidisciplinary care for patients with head and neck cancer.

Younger patients, women, and white patients with HPV-related cancers had superior survival at 5 years, indicating that increased HPV vaccination and better access to cancer screening and treatment are likely needed to reduce survival disparities

Michael Bouvet, MD, professor of surgery, University of California, San Diego, discusses the diagnosis of thyroid cancer.

While the incidence of HPV-related oropharyngeal cancer is increasing, the risk for developing the disease remains low for most people.

Gregory A. Daniels, MD, PhD, medical oncologist, associate professor of medicine, UC San Diego Health, discusses the role of immunotherapy for patients with head and neck cancer.

Joseph A. Califano, MD, professor of surgery, University of California, San Diego, discusses the role of multidisciplinary care for patients with head and neck cancer.

Loren K. Mell, MD, explains his research for risk-stratifying patients with head and neck cancer.

Kathryn A. Gold, MD, medical oncologist, associate professor of medicine, UC San Diego Heath, discusses approaching patients with HPV-positive head and neck cancer.

Loren K. Mell, MD, assistant professor, Department of Radiation Medicine and Applied Sciences, University of California, San Diego School of Medicine, discusses risk stratification for patients with head and neck cancer.

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the unmet need facing the quality of life for patients with head and neck cancer.

Michael Bouvet, MD, professor of surgery, University of California, San Diego, discusses the remaining challenges with thyroid cancer surgery.

Assuntina G. Sacco, MD, assistant professor of medicine, medical oncologist, UC San Diego Health, discusses upfront treatment for patients with head and neck cancer.

Joseph A. Califano, MD, professor of surgery, University of California, San Diego, discusses the future of surgery in head and neck cancer.

Kathryn A. Gold, MD, discusses HPV status and prognosis, as well recognizing risk factors of virally-associated head and neck squamous cell carcinoma.

Gregory Daniels, MD, PhD, discusses the current treatment landscape of thyroid cancer and the development of immunotherapy for patients with this disease.

Gregory A. Daniels, MD, PhD, medical oncologist, associate professor of medicine, UC San Diego Health, discusses treatment options for patients with thyroid cancer.

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the role of entrectinib in treating patients with head and neck cancer.

Ezra Cohen, MD, discusses the role of immunotherapy, the potential of entrectinib, and the importance of multidisciplinary teams for the treatment of patients with head and neck cancer.

Daniel Zandberg, MD, discusses results from the HAWK study as well as current combination approaches for patients with head and neck cancer.

Although surgery and radiotherapy are standard treatment modalities for grade T1/T2 oral cavity cancer, both approaches have well-documented limitations, including their association with adverse effects that lower quality of life for patients.

The presence of metastatic lymph nodes was directly correlated with poorer survival in patients with oral cancer, according to findings published in the Journal of Clinical Oncology.

The UK’s National Institute for Health and Care Excellence has issued guidelines recommending against nivolumab (Opdivo), lenvatinib (Lenvima), and sorafenib (Nexavar).

Kathryn A. Gold, MD, medical oncologist, associate professor of medicine, UC San Diego Heath, discusses the current state of human papilloma virus (HPV)-related head and neck cancer.

Dan Zandberg, MD, assistant professor of medicine, the University of Maryland School of Medicine, discusses biomarker development in patients with head and neck cancer.

Dan Zandberg, MD, assistant professor of medicine, University of Maryland School of Medicine, discusses the role of immunotherapy in head and neck cancer.

Dan Zandberg, MD, assistant professor of Medicine, the University of Maryland Medical Center, discusses the role of durvalumab (Imfinzi) in patients with metastatic head and neck cancer.

The incidence of mouth and throat cancer is on the rise due to transmission of the human papilloma virus, but physicians at Memorial Sloan Kettering Cancer Center have managed to significantly reduce the intensity of treatment and improve quality of life for these patients.

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the phase III KEYNOTE-040 trial in head and neck cancer.